Related Experiment Video
Updated: Oct 16, 2025

04:50
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
Published on: January 17, 2025
445
[Ⅱ.Treatment for Recurrent Cholangiocarcinoma]
Nobuyuki Watanabe1, Yukihiro Yokoyama, Tsuyoshi Igami
1Division of Surgical Oncology, Dept. of Surgery, Nagoya University Graduate School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 17, 2021
Abstract
No abstract available in PubMed .
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
141
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
141
Chronic Bowel Disorders: Introduction
567
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
567
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

